BINV — BioInvent International AB Share Price
0.000.00%
Last trade - 00:00- SEK1.93bn
- SEK1.08bn
- SEK44.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.18 | ||
| Price to Tang. Book | 2.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -52.69% | ||
| Return on Equity | -39.11% | ||
| Operating Margin | -1054.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 147.37 | 19.38 | 326.13 | 71.46 | 44.69 | 71.27 | 472.23 | -13.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Directors
- Leonard Kruimer CHM (63)
- Martin Welschof CEO (58)
- Stefan Ericsson CFO (56)
- Kristoffer Rudenholm Hansson SVP (45)
- Bjorn Frendeus CSO (46)
- Andres McAllister OTH (63)
- Vessela Alexieva DRC (60)
- Anette Martensson DRC (39)
- Kristoffer Bissessar IND (51)
- Dharminder Chahal IND (45)
- Thomas Hecht IND (71)
- Vincent Ossipow IND (51)
- Bernd Seizinger IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 14th, 1997
- Public Since
- June 12th, 2001
- No. of Employees
- 114
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 65,804,362
- Address
- The Gamma Building, Ideongatan 1, LUND, 223 70
- Web
- https://www.bioinvent.com/
- Phone
- +46 462868550
- Contact
- Cecilia Hofvander
- Auditors
- KPMG AB
Upcoming Events for BINV
Q1 2025 BioInvent International AB Earnings Release
BioInvent International AB Annual Shareholders Meeting
Q2 2025 BioInvent International AB Earnings Release
Similar to BINV
2cureX AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
FAQ
What is the BioInvent International AB share price?
As of Today at 19:35 UTC, shares in BioInvent International AB are trading at SEK29.30. This share price information is delayed by 15 minutes.
How has the BioInvent International AB share price performed this year?
Shares in BioInvent International AB last closed at SEK29.30 and the price had moved by +18.38% over the past 365 days. In terms of relative price strength the BioInvent International AB share price has outperformed the FTSE Global All Cap Index by +15.42% over the past year.
What are the analyst and broker recommendations for BioInvent International AB?
The overall consensus recommendation for BioInvent International AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the BioInvent International AB dividend yield?
BioInvent International AB does not currently pay a dividend.
Does BioInvent International AB pay a dividend?
BioInvent International AB does not currently pay a dividend.
When does BioInvent International AB next pay dividends?
BioInvent International AB does not currently pay a dividend.
How do I buy BioInvent International AB shares?
To buy shares in BioInvent International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioInvent International AB?
As of the previous close price of SEK29.30, shares in BioInvent International AB had a market capitalisation of SEK1.93bn.
Where are BioInvent International AB shares listed?
Here are the trading details for BioInvent International AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BINV
What kind of share is BioInvent International AB?
Based on an overall assessment of its quality, value and momentum BioInvent International AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioInvent International AB share price forecast for 2025?
The analyst consensus target price for shares in BioInvent International AB is SEK86.67. That is 195.8% above the last closing price of SEK29.30.
Analysts covering BioInvent International AB currently have a consensus Earnings Per Share (EPS) forecast of SEK9.74 for the next financial year.
Find out moreWhat is the trend in the BioInvent International AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioInvent International AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -33.12%.
As of the last closing price of SEK29.30, shares in BioInvent International AB were trading -20.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioInvent International AB PE Ratio?
The BioInvent International AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK29.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioInvent International AB?
BioInvent International AB's management team is headed by:
- Leonard Kruimer - CHM
- Martin Welschof - CEO
- Stefan Ericsson - CFO
- Kristoffer Rudenholm Hansson - SVP
- Bjorn Frendeus - CSO
- Andres McAllister - OTH
- Vessela Alexieva - DRC
- Anette Martensson - DRC
- Kristoffer Bissessar - IND
- Dharminder Chahal - IND
- Thomas Hecht - IND
- Vincent Ossipow - IND
- Bernd Seizinger - IND